Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study
Feb 19, 2013 - Gilead Sciences today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus infection who failed prior treatment.
Join the discussion below, or Read more at Drugs.com.
#1 Feb 19, 2013
Thank God, thank God and good doctors
Add your comments below
|Lower Availability of Omega-3 fatty Acids Assoc...||16 hr||Nataly||1|
|$160B deal to combine Pfizer and Allergan raise...||Thu||Mite Be||21|
|CDC: 'Alarming' increase in STDs||Wed||Belles Echoes||125|
|Pfizer to buy Allergan in $160 billion deal||Nov 25||Cordwainer Trout||6|
|Press release distribution, EDGAR filing, XBRL,...||Nov 23||Buckle Up||1|
|Two murdered at Texas campsite are from Oceanside||Nov 19||James McMillan||1|
|US survey shows higher rate of autism in children||Nov 13||Vaccines Autism S...||1|
Find what you want!
Search Biotech Forum Now
Copyright © 2015 Topix LLC